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http://dx.doi.org/10.1016/j.jmii.2012Good’s syndrome is an acquired immunodeficiency state associated with thymoma and charac-
terized by recurrent pulmonary infections. We describe a 67-year-old woman who presented
with respiratory symptoms caused by concomitant disseminated cytomegalovirus infection
and Pneumocystis jiroveci pneumonia 38 months after thymectomy for a thymoma. Immuno-
logic analysis revealed hypogammaglobulinemia with absent B-cell population as demon-
strated by flow cytometry, consistent with Good’s syndrome. Following treatment with
sulfamethoxazole/trimethoprim and ganciclovir, the patient improved with resolution of her
respiratory symptoms. However, the patient subsequently experienced additional infections,
necessitating additional subsequent hospital admissions. During the last admission, intrave-
nous immunoglobulin (IVIG) replacement therapy was initiated and continued after discharge.ulmonary and Critical Care Medicine, Tri-Service General Hospital, Number 325, Section 2, Cheng-
.
h.edu.tw (W.-L. Su).
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230 C.-H. Wang et al.Infection has been prevented for one year after beginning IVIG replacement therapy. This case
reveals that in patients with combined humoral and cell-mediated immune deficiency,
concomitant infection with different pathogens is not unusual, and immediate specific therapy
is important. Periodic IVIG infusion, to maintain adequate Ig levels, is recommended.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Patients with thymoma can experience various forms of
paraneoplastic syndromes. The three most common are
myasthenia gravis, pure red cell aplasia, and hypogamma-
globulinemia.1 Hypogammaglobulinemia occurs in 3e6% of
patients with thymoma. This association, first reported by
Robert Good and colleagues in 1954, is referred to as
Good’s syndrome,2 and is characterized by low to absent B-
cell numbers in the peripheral blood, hypogammaglobulin-
emia, and defects in cell-mediated immunity, resulting in
recurrent infection by various microbial pathogens. We
herein present the successful treatment of a patient with
Good’s syndrome infected with concomitant disseminated
cytomegalovirus (CMV) infection and Pneumocystis jiroveci
pneumonia (PJP), and discuss the use of prophylactic
immunoglobulin replacement therapy for such patients.Figure 1. A mass (about 13.8  9.5  6.0 cm) in the pre-
vascular space of the left anterior mediastinum consistent with
a thymoma.Case report
A 67-year-old woman was admitted to our hospital because
of dyspnea and fever for 1 day. She had been in good health
until 6 years earlier, when she started to experience
a refractory productive cough. At that time, chest
computed tomography performed showed a heterogeneous
soft-tissue mass (approximately 13.8  9.5  6.0 cm) in the
prevascular space of the left anterior mediastinum,
consistent with a thymoma (Fig. 1). Thymectomy was per-
formed through a median sternotomy. Histopathological
diagnosis of the resected tumor was consistent with a thy-
moma, type AB, based on the World Health Organization
classification. The tumor had infiltrated into, but not
through, the capsule. She received adjuvant radiation
therapy after the operation. Following completion of the
therapy, the patient remained in good health until 3 months
after the operation, when she was admitted for PJP and
herpes zoster infection of the skin. She was subsequently
admitted to the hospital twice due to sepsis by Strepto-
coccus pneumoniae and CMV infection on the 27th and 35th
months. Thirty-eight months after thymectomy, she was
admitted again. Physical examination on admission
revealed a fever of 39.6 C, pulse rate 116 bpm, blood
pressure 92/60, respiratory rate 28, and SpO2: 96% under
3 L/min nasal canula, moist skin, and coarse crackles in the
bilateral lower chest. The leukocyte count was 13,240/mL
with 86% neutrophils, 9% bands, a platelet count of
230,000/mL, and a C-reactive protein level of 10.38 mg/dL.
Arterial blood gas showed a pH of 7.39, PaCO2 of 44 mmHg,
PaO2 of 75 mmHg, and SaO2 of 96% while breathing 60%
supplemental oxygen via a face mask. Chest computedtomography on admission showed diffuse reticulonodular/
ground-glass opacities and interstitial infiltration bilater-
ally, suggestive of chronic interstitial lung disease with
superimposed acute infection (Fig. 2). Broad-spectrum
antibiotic treatment with piperacillin/tazobactam was
administered. Since her medical history indicated repeated
episodes of pneumonia with various pathogens, including
opportunistic pathogens, the immune status of the patient
was assessed during the hospitalization. Significantly
decreased levels of IgG (375 mg/dL), IgM (5 mg/dL), IgA
(38 mg/dL), and IgE (<5 IU/mL) were noted. Evaluation of
peripheral lymphocytes by flow cytometry revealed the
lack of B-cell lineage (negative for CD19 and positive for
CD3) with reversed T helper to suppressor ratio (0.32). CD4
T-cell number was 452/mL. Antibody to human immunode-
ficiency virus (HIV) was negative. Combined with the
previous thymoma history and immune abnormality, these
results established a diagnosis of Good’s syndrome.
Despite treatment with broad-spectrum antibiotics, the
fever persisted with little improvement of the symptoms.
Polymerase chain reaction (PCR) using real-time TaqMan
PCR on blood, urine, and sputum specimens were positive
for CMV, consistent with a diagnosis of disseminated CMV
infection. The concomitant diagnosis of PJP was estab-
lished by a positive sputum PCR for P. jiroveci. Sulfame-
thoxazole/trimethoprim and ganciclovir were prescribed
accordingly, and symptoms improved after treatment. The
patient was then discharged in stable condition, but
Figure 2. Patchy fibrotic lesions with traction bronchiectasis
in both upper lung fields, with destruction and multiple blebs.
Good’s syndrome with PJP and CMV 231experienced another episode of infection (Table 1) neces-
sitating additional hospital admissions. To prevent recur-
rent pulmonary infections and sequela of impaired lung
function, she was begun on intravenous immunoglobulin
(IVIG) infusions at 500 mg/kg per day for 5 days. IVIG
therapy was continued periodically at an outpatient basis
to maintain adequate immunoglobulin levels. Infection has
not recurred for 1 year after the start of regular IVIG
replacement therapy. The numerous episodes of serious
infections requiring hospitalization, all of which occurred
before the initiation of Ig replacement therapy, are listed in
Table 1. The patient continues to receive regular IVIG
supplementation and infection surveillance every 3 months.
In the 1-year follow-up after initiating periodic IVIG
replacement, this regimen appears to be effective in pre-
venting subsequent infections, although further studies will
be required to validate this therapy.Discussion
Good’s syndrome (immunodeficiency with concomitant thy-
moma) is a combined humoral and cellular immunodeficiencyTable 1 Infectious episodes requiring hospitalization
Time after
thymectomy (mo)
Duration of
hospitalization
Infectious disease
3th 28 Pneumonia
27th 7 Pneumonia with seps
35th 13 Pneumonia and CMV
38tha 16 Pneumonia and CMV
41th 6 Pneumonia
46th 7 Pneumonia and CMV
48th 36 Pneumonia with acut
53thb 10 Pneumonia
a Good’s syndrome was diagnosed at this admission.
b Intravenous immunoglobulin replacement therapy started at this athat is now classified as an entity separate from common
variable immune deficiency (CVID).3 Good’s syndrome
typically occurs in the 4th or 5th decade of life, preceding
or following the diagnosis of a thymoma,2 and is seen with
equal frequency in men and women. In contrast to other
paraneoplastic syndromes associated with thymoma, the
immunologic abnormalities of Good’s syndrome are not
corrected by corticosteroid treatment or thymectomy.4
The main characteristics of Good’s syndrome are hypo-
gammaglobulinemia due to a low or absent B cell count and
variable defects in cell-mediated immunity, an abnormal
CD4þ/CD8þ T cell ratio, and an impaired T-cell mitogenic
response. However, the underlying pathogenesis of Good’s
syndrome remains unclear. At least two possible pathogenic
mechanisms have been proposed. The first potential
mechanism is that cytokines, possibly released by bone
marrow stromal cells, inhibit both thymic and B-cell
precursor growth and differentiation. The second potential
mechanism is suggested by the observation that T cells
isolated from patients with thymoma can inhibit both pre-B
cell growth and immunoglobulin production by B cells.5
Since both humoral and cell immunity are compromised,
individuals with Good’s syndrome are susceptible to various
infections, including opportunistic viral, bacterial, and
fungal infections.
Tarr et al2 reported that sinopulmonary infection with
Haemophilus influenzae was the most common infectious
disease among 51 patients with immunodeficiency and
thymoma. Other infections observed in their patients were
CMV, PJP, infectious diarrhea, and tuberculosis.2 Our
patient had a history of recurrent pneumonia caused by
bacterial, fungal, and viral pathogens, suggestive of
immunocompromised status. Low levels of immunoglobulin
and lack of B cell lineage by flow cytometry confirmed the
diagnosis of Good’s syndrome. The interstitial pneumonitis
improved after treatment with sulfamethoxazole/trimeth-
oprim and ganciclovir for concurrent PJP and CMV infec-
tions. Follow-up chest high-resolution computed
tomography, performed 3 months after discharge, showed
bronchiectasis and interstitial lung disease, consistent with
prior lung injury from prior recurrent infections.
Adequate replacement of immunoglobulin has been
shown to reduce the incidence of pneumonia in CVID.6
The efficacy of this therapy has not been validated forPathogen
Pneumocystis jiroveci
is Streptococcus pneumoniae
viremia with sepsis CMV
viremia with sepsis P. jiroveci and CMV (PCR in blood,
urine, sputum)
Unspecified bacteria
viremia with sepsis CMV
e respiratory failure P. jiroveci and CMV
Unspecified bacteria
dmission.
232 C.-H. Wang et al.Good’s syndrome, although some retrospective data would
support such a regimen.4 Since Good’s syndrome is similar
to CVID with regard to immune abnormality, we hypoth-
esized that Good’s syndrome might also benefit from
IVIG therapy. Therefore, the patient was administered
IVIG infusions to maintain serum IgG levels of at least
500 mg/dL, as for patients with CVID, along with
surveillance for signs of infection. Since the initiation of
periodic IVIG replacement therapy, further infections
have been prevented.
Previous reports revealed that both humoral and cell-
mediated immunity are critical for the control of CMV
infections.7,8 Preemptive treatment for CMV viraemia has
been documented to prevent CMV disease in solid organ
transplant recipients.9 Although we are not aware of any
reports of the treatment of disseminated CMV infection in
Good’s syndrome, we aggressively treated our patient for
disseminated CMV infection since patients with Good’s
syndrome are also severely immunocompromised, similar to
that seen in solid organ transplant recipients.
P. jiroveci can cause a lung infection in people with
impaired immunity, especially in people with cancer, indi-
viduals with AIDS, and users of immunosuppressive medi-
cations. While it is not surprising that a patient with Good’s
syndrome presented with PJP, few such case reports have
been described.2 In non-HIV immunocompromised patients
(specifically, adults with acute leukemia or solid organ
transplantation), prophylaxis for PJP with trimethoprim/
sulfamethoxazole, an antibiotic effective against PJP,
significantly reduced the occurrence of PJP by more than
90%.10 It is still uncertain whether other Good’s syndrome
patients could benefit from such a prophylaxis regimen.
Our case reveals that in adults with a history of a thy-
moma who present with recurrent pulmonary infections,
Good’s syndrome should be taken into consideration. As
demonstrated by our patient’s medical history of recurrent
infections (Table 1), a patient with Good’s syndrome can
present with respiratory infections caused by a wide range
of pathogens, including opportunistic pathogens. In addi-
tion to immediate treatment of the specific infection with
appropriate antimicrobial agents, chronic IVIG replacement
should be considered to prevent recurrent infectionsalthough further studies will be needed to validate the
benefit of this therapy.
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